Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

FUJIFILM

Financial Results (Consolidated) for the Three Months Ended June 30, 2026

FUJIFILM Holdings Corporation August 6, 2026

Teiichi Goto URL: https://holdings.fujifilm.com/en

President and Chief Executive Officer

Projected date of the beginning of cash dividends: -

Reference materials regarding operating results of the current quarter to be prepared: Yes

Meeting to explain operating results of the current quarter to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

1. Results of the Three Months Ended June 30, 2026 (From April 1, 2026 to June 30, 2026)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings	
		%		%		%		%
1st Quarter ended June 30, 2026	826,493	10.3	51,184	(32.0)	52,100	(27.6)	37,424	(30.4)
1st Quarter ended June 30, 2025	749,482	0.1	75,291	21.1	71,954	0.3	53,767	(11.5)

Note: Comprehensive income

1st Quarter ended June 30, 2026 ¥88,782 million (+58.3%) 1st Quarter ended June 30, 2025 ¥56,081 million (-72.4%)

	Net income attributable to FUJIFILM Holdings per share	Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)
	Yen	Yen
1st Quarter ended June 30, 2026	31.26	31.23
1st Quarter ended June 30, 2025	44.63	44.59

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Total assets	Total equity (Net asset)	FUJIFILM Holdings shareholders' equity	FUJIFILM Holdings shareholders' equity ratio to total assets
				%
As of June 30, 2026	6,167,301	3,903,549	3,898,484	63.2
As of March 31, 2026	6,053,776	3,844,385	3,839,550	63.4

2. Cash Dividends

	Cash dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year End	Year Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2026	-	35.00	-	35.00	70.00
Year ending March 31, 2027	-				
Year ending March 31, 2027 (Forecast)		37.50	-	37.50	75.00

Note: Changes in dividends forecast during the quarter under review: None

.

3. Forecast for the Fiscal Year Ending March 31, 2027 (From April 1, 2026 to March 31, 2027)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings		Net income attributable to FUJIFILM Holdings per share
		%		%		%		%	Yen
For the Year ending March 31, 2027	3,560,000	6.0	365,000	4.2	375,000	2.3	280,000	1.2	234.19

Note: Changes in forecast which was recently announced: Yes

Note: The weighted-average number of shares used in calculating net income attributable to FUJIFILM Holdings shareholders per share is based on the number of shares outstanding as of June 30, 2026, excluding treasury shares.

Notes

(1) Significant changes in the scope of consolidation during the period: None

(2) Adoption of simplified method of accounting or specific accounting treatments: None

(3) Changes in accounting principles

1. Changes in accounting policies accompanied by revisions of accounting standards: None
2. Changes in accounting policies other than 1. above: None

(4) Number of shares outstanding

1. Issued (including treasury stock):	As of June 30, 2026	1,234,150,284	As of March 31, 2026	1,243,877,184
2. Treasury stock:	As of June 30, 2026	38,542,505	As of March 31, 2026	38,547,368
3. Average number of shares:	1st Quarter ended June 30, 2026	1,195,821,475	1st Quarter ended June 30, 2025	1,203,561,229

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have an intention of guaranteeing the realization of the forecasts. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecasts and warnings for users of the forecasts are mentioned in the page 6, (3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results in 1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER.

[INDEX]

1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER

(1) Explanation on Consolidated Operating Results

Amount Unit: Billions of yen

	Three months ended June 30, 2026		Three months ended June 30, 2025		Change (Amount)	Change (%)
Domestic revenue	30.7%	253.7	34.3%	256.9	(3.1)	(1.2%)
Overseas revenue	69.3%	572.8	65.7%	492.6	80.2	16.3%
Revenue	100.0%	826.5	100.0%	749.5	77.0	10.3%
Operating income	6.2%	51.2	10.0%	75.3	(24.1)	(32.0%)
Income before income taxes	6.3%	52.1	9.6%	72.0	(19.9)	(27.6%)
Net income attributable to FUJIFILM Holdings	4.5%	37.4	7.2%	53.8	(16.3)	(30.4%)
Exchange rates (Yen / US$)		¥159		¥145		¥14
Exchange rates (Yen / Euro)		¥185		¥164		¥21

In the three months ended June 30, 2026, the Fujifilm Group recorded ¥826.5 billion in consolidated revenue (up 10.3% year-on-year) reflecting revenue increases in the Medical Systems, Semiconductor Materials and Imaging businesses.

Operating income decreased to ¥51.2 billion (down 32.0% year-on-year), despite higher earnings in the Electronics and Imaging segments, primarily due to increased fixed costs in the Bio CDMO business in the Healthcare, one-time costs incurred to strengthen the organizational structure of Business Innovation segment, and the impact of rising raw material costs. Consolidated income before income taxes amounted to ¥52.1 billion (down 27.6% year-on-year), and consolidated net income attributable to FUJIFILM Holdings totaled ¥37.4 billion (down 30.4% year-on-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen during the current quarter were ¥159 and ¥185, respectively.

Revenue by Operating Segment

Amount Unit: Billions of yen

Segment	Three months ended June 30, 2026	Three months ended June 30, 2025	Change (Amount)	Change (%)
Healthcare	256.8	228.5	28.4	12.4%
Electronics	127.7	102.1	25.5	25.0%
Business Innovation	273.2	273.6	(0.3)	(0.1%)
Imaging	168.8	145.3	23.5	16.2%
Consolidated Total	826.5	749.5	77.0	10.3%

Operating Income (Loss) by Operating Segment

Amount Unit: Billions of yen

Segment	Three months ended June 30, 2026	Three months ended June 30, 2025	Change (Amount)	Change (%)
Healthcare	(12.7)	4.3	(17.0)	-
Electronics	31.1	22.5	8.6	38.2%
Business Innovation	(1.4)	15.6	(17.0)	-
Imaging	43.4	41.8	1.6	3.9%
Corporate Expenses etc.	(9.2)	(8.8)	(0.4)	-
Consolidated Total	51.2	75.3	(24.1)	(32.0%)

Healthcare

In the Healthcare segment, consolidated revenue amounted to ¥256.8 billion (up 12.4% year-on-year).

Consolidated operating loss amounted to ¥12.7 billion.

The Medical Systems business posted higher revenue. Sales of endoscopes continued to increase in key markets, including Japan, the U.S. and Europe. Medical IT sales also grew, with solid sales of systems and services, mainly for the *SYNAPSE* Picture Archiving and Communication System (PACS), in Japan, Europe and other markets, alongside sales of ultrasound diagnostic equipment, which experienced strong sales in Japan and Europe. In April 2026, we launched *SYNAPSE LEAD Cloud*, a cloud-based picture archiving and communication system, as a new addition to our PACS lineup. Moreover, in June 2026, we released the upper gastrointestinal scope *EG-860Z* and the lower gastrointestinal scopes *EC-860ZP/M* and *EC-860ZP/L* as a new lineup of magnifying endoscopes for *ELUXEO*, the endoscope system with LED light source. We will continue to leverage our proprietary technologies to provide a wide range of products and services that meet the various demands of medical settings, to contribute to further improving diagnostic efficiency, enhancing the quality of healthcare, and maintaining and promoting people's health.

Sales increased in the Bio CDMO business, driven by the expanding operations of the large-scale facilities at the North Carolina site in the U.S., which commenced operations in the previous fiscal year. In June 2026, we announced the co-development with HORIBA, Ltd. of a high-sensitivity inline Raman measurement system that enables real-time visualization of the cell culture and purification processes in biopharmaceutical manufacturing. Moving forward, we will proceed with verification for practical implementation and contribute to the stable production and reduction of manufacturing costs of high-quality biopharmaceuticals, including antibody drugs, through the visualization of manufacturing processes and the establishment of advanced data analysis technologies.

The LS (Life Sciences) Solutions business[*1] posted higher revenue due to the life sciences business delivering higher sales of culture media driven by increased usage by major pharmaceutical companies, alongside strong sales of *iCell* (iPS cell－derived differentiated cells) for drug discovery support backed by robust drug discovery needs, as well as the consumer healthcare business seeing strong sales of cosmetics. In May 2026, we opened the new U.S. headquarters in Wisconsin of FUJIFILM Cellular Dynamics, Inc., a leading company in the development and manufacturing of iPS cells. Through this, we will significantly enhance our manufacturing capacity for iPS cell-derived differentiated cells for drug discovery support, while also establishing cutting-edge laboratory facilities to support R&D in this field and process development for cell therapies, thereby supporting customers from the early stages of development. Furthermore, in May this year, we obtained manufacturing and marketing approval in Japan for the regenerative medical product *SAVYSCUS® Injection.* This product is indicated for meniscal injuries for which meniscectomy is considered appropriate and is the first regenerative medical product approved in Japan[*2] for meniscal injury. Through *SAVYSCUS® Injection*, we aim to provide new treatment options for patients with meniscal injury and to contribute to improving and maintaining human health by offering a broad range of orthopedic solutions spanning prevention, diagnosis, and treatment.

[*1] The LS Solutions business comprises Life Sciences business, Pharmaceutical business, Consumer Healthcare business and CRO (Contract Research Organization) business.

[*2] The first regenerative medical product for meniscal injury to obtain manufacturing and marketing approval in Japan under the Pharmaceutical and Medical Device Act.

Electronics

In the Electronics segment, consolidated revenue amounted to ¥127.7 billion (up 25.0% year-on-year).

Consolidated operating income amounted to ¥31.1 billion (up 38.2% year-on-year).

In addition to the use of semiconductors in a wide range of products today such as smartphones, personal computers, automobiles and home appliances, the semiconductor market is now undergoing significant growth due to rising demand for AI semiconductors. By steadily capturing advanced materials demand for AI semiconductors, our Semiconductor Materials business achieved growth that significantly outpaced the market average in the previous fiscal year. Revenue increased substantially during the fiscal year under review, driven by sustained strong sales to major foundries alongside a recovery in sales to major semiconductor manufacturers in the U.S. and South Korea. By product, sales expanded for our copper interconnect CMP slurry and NTI developers, both of which hold the top global market share, as well as advanced photoresists, driven by miniaturization and the increasing number of interconnect layers. With respect to back-end materials, sales of liquid polyimide for interlayer insulation films used in inter-chip connections also increased, driven by expanding demand for advanced packaging for AI semiconductors. In May 2026, we participated in ECTC 2026, an international conference on semiconductor packaging-related technologies. Aiming to achieve miniaturization in next-generation packaging to advance AI semiconductors, we presented the results of joint research conducted with imec, an international research institute for advanced semiconductors. Furthermore, we announced that we had newly developed a PFAS-free PBO (polybenzoxazole) insulating film material, thereby making all materials in the *ZEMATES* photosensitive insulating materials lineup PFAS-free.

The AF (Advanced Functional) Materials business posted higher revenue due to strong sales of data tapes to major IT companies, amid increasing data volume associated with the widespread adoption of AI. In June 2026, we launched *Round Prescale*, a circular type designed to match semiconductor wafer shapes, as a new addition to our *Prescale* pressure measurement film lineup, designed for pressure inspection in semiconductor manufacturing processes. We will continue to contribute to improving and stabilizing customers' manufacturing quality by developing and providing products that enable the streamlining of inspection operations in development and manufacturing sites.

Business Innovation

In the Business Innovation segment, consolidated revenue amounted to ¥273.2 billion (down 0.1% year-on-year).

Consolidated operating loss amounted to ¥1.4 billion.

The Business Solutions business posted higher revenue primarily due to solid performance in overseas ERP system sales and implementation support services, despite the absence of the temporary demand for BPO services overseas recorded in the same period of the previous fiscal year. In May 2026, we commenced the rollout of *REiLI Business*, an AI technology brand centered on digital technologies including AI, while also opening the REiLI Business Hub in Yokohama Minatomirai as a base for its implementation and value creation. With the aim of creating value closely aligned with real-world business operations, and in order to advance customers' AI implementation more rapidly and reliably, this site will bring together experts in technology development, product planning and implementation to accelerate the value creation cycle by driving the entire process from ideation through verification to the commercialization of products and services.

The Office Solutions business posted lower revenue mainly due to a decline in exports to Europe and the U.S. as well as lower sales in China.

Revenue of the Graphic Communications business increased due to sales expansion of inkjet printheads in the inkjet field, among other factors. In June 2026, we announced the opening of the Revoria Experience Center, a new site in India responsible for high-value-added printing verification and human resource development. Through print output verification aimed at supporting diverse paper types and realizing high-value-added printed materials using special toners, as well as the training of operators and designers, we will contribute to expanding our customers' businesses and improving their productivity in India's growing printing market.

Imaging

In the Imaging segment, consolidated revenue amounted to ¥168.8 billion (up 16.2% year-on-year).

Consolidated operating income amounted to ¥43.4 billion (up 3.9% year-on-year).

The Consumer Imaging business posted higher revenue due to sales expansion of the *instax* instant photo systems. In addition to strong sales of mid-to-high-priced products—including *instax mini Evo*, which has maintained its popularity since its launch in 2021, and *instax WIDE 400*, which added a new color JET BLACK to its lineup this fiscal year—sales of film also expanded due to increased production capacity. In April 2026, we launched *instax mini 13*, an entry-level analog instant camera with renewed design and features, which has been well received globally. We will continue to expand the world of *instax*, enabling people to enjoy instant photo printing and further enhancing the value and joy of photography

The Professional Imaging business posted higher revenue due to expanding sales of digital cameras, particularly in Asia where demand was robust. In addition to mainstay models launched in the previous fiscal year, such as *FUJIFILM X-E5* and *FUJIFILM X-T30 III*, sales also trended strongly for *FUJIFILM X100VI*, a long-selling model that has maintained high popularity. We will continue to provide attractive products for digital camera users and the video production industry by delivering outstanding image quality through the large format sensors in the *GFX* series and achieving the best balance of image quality and size through the *X* series, while also creating cameras with new concepts, such as *FUJIFILM GFX100RF*, *X half* and *FUJIFILM GFX ETERNA 55*.

(2) Explanation on the Consolidated Financial Position

At the end of the three months ended June 30, 2026, total assets increased by ¥113.5 billion compared with the end of the previous fiscal year (March 31, 2026) to ¥6,167.3 billion, mainly due to increases in property, plant and equipment and inventories. Total liabilities increased by ¥54.4 billion to ¥2,263.8 billion. FUJIFILM Holdings shareholders' equity increased by ¥58.9 billion to ¥3,898.5 billion. The current ratio increased by 0.2 percentage points to 136.8%, the debt-equity ratio increased by 0.6 percentage points to 58.1%, and the equity ratio decreased by 0.2 percentage points to 63.2% compared with the end of the previous fiscal year. The Company is maintaining a stable level of asset liquidity and a sound capital structure.

(Cash Flows)

Amount Unit: Billions of yen

	Three months ended June 30, 2026	Three months ended June 30, 2025	Change
Net cash provided by operating activities	92.3	94.8	(2.5)
Net cash used in investing activities	(124.9)	(120.0)	(4.9)
Net cash provided by (used in) financing activities	6.3	20.1	(13.8)

In the three months ended June 30, 2026, net cash provided by operating activities totaled ¥92.3 billion. Net cash used in investing activities amounted to ¥124.9 billion due to the acquisition of property, plants, equipment and other factors. As a result, free cash flow, or the sum of cash flow from operating and investing activities, was negative ¥32.6 billion. Net cash provided by financing activities amounted to ¥6.3 billion, due to an increase in long-term debt and other factors.

As a result, cash and cash equivalents at the end of the three months ended on June 30, 2026 amounted to ¥150.7 billion, down ¥19.9 billion from the end of the previous fiscal year (March 31, 2026).

(3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results
(Consolidated financial forecast for the fiscal year ending March 31, 2027)

Amount Unit: Billions of yen

	Previous Forecast (A) (announced on May 12, 2026)	Revised Forecast (B)	Change (B-A)	Change (%)	(Reference) Actual Results for Fiscal Year ended March 31,2026
Revenue	3,470.0	3,560.0	90.0	2.6%	3,357.0
Operating income	365.0	365.0	-	-	350.2
Income before income taxes	375.0	375.0	-	-	366.6
Net income attributable to FUJIFILM Holdings	280.0	280.0	-	-	276.7
Net income attributable to FUJIFILM Holdings per share	¥234.19	¥234.19	¥-	-	¥229.65
ROE (%)	7.8	7.8	-	-	7.7
ROIC (%)	5.6	5.6	-	-	5.5
Exchange rates (Yen / US$)	¥150	¥156	¥6	-	¥151
Exchange rates (Yen / Euro)	¥175	¥181	¥6	-	¥175

For the fiscal year ending March 31, 2027, the Company revised its consolidated revenue upward to ¥3,560.0 billion in consolidated revenue (up 2.6% from the previous forecast), reflecting factors such as strong sales in the Electronics as well as exchange rate fluctuations. Operating income is projected to remain unchanged from the previous forecast at ¥365.0 billion, because while sales increases in the Electronics and gains on the sale of non-core assets in the Business Innovation are expected, these will be offset by delayed profitability in the Bio CDMO business and the impact of rising semiconductor memory prices. Income before income taxes is expected to be ¥375.0 billion, and net income attributable to FUJIFILM Holdings is expected to be ¥280.0 billion.

The projected currency exchange rates for the U.S. dollar and the euro against the yen during the fiscal year ending March 31, 2027 are ¥156 and ¥181, respectively.

2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION

(1) Significant Changes in the Scope of Consolidation During the Period:
None.

(2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments:
None.

(3) Changes in Accounting Principles:
None.

3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION:
None.

4. CONSOLIDATED FINANCIAL STATEMENTS

(1) Consolidated Balance Sheets

Amount Unit: Millions of yen

	As of June 30, 2026	As of March 31, 2026	Change
ASSETS			
Current assets:			
Cash and cash equivalents	150,651	170,553	(19,902)
Notes and accounts receivable:			
Trade	686,793	742,721	(55,928)
Lease receivables	31,479	31,750	(271)
Affiliated companies	1,829	2,737	(908)
Allowance for credit losses	(13,624)	(14,693)	1,069
	706,477	762,515	(56,038)
Inventories	667,065	600,796	66,269
Prepaid expenses and Other	195,584	185,169	10,415
Total current assets	1,719,777	1,719,033	744
Investments and long-term receivables:			
Investments in and advances to affiliated companies	37,555	37,617	(62)
Investment securities	45,026	43,672	1,354
Long-term lease receivables	48,636	49,181	(545)
Other long-term receivables	77,013	76,831	182
Allowance for credit losses	(1,455)	(1,511)	56
Total investments and long-term receivables	206,775	205,790	985
Property, plant and equipment:			
Land	121,864	121,419	445
Buildings and structures	1,208,813	1,173,654	35,159
Machinery, equipment and others	2,134,308	1,989,906	144,402
Construction in progress	914,292	979,735	(65,443)
	4,379,277	4,264,714	114,563
Less accumulated depreciation	(1,982,394)	(1,956,406)	(25,988)
Total property, plant and equipment	2,396,883	2,308,308	88,575
Other assets:			
Operating lease right-of-use assets	133,238	130,157	3,081
Goodwill, net	1,006,314	997,068	9,246
Other intangible assets, net	148,998	151,175	(2,177)
Other	555,316	542,245	13,071
Total other assets	1,843,866	1,820,645	23,221
Total assets	6,167,301	6,053,776	113,525

Amount Unit: Millions of yen

	As of June 30, 2026	As of March 31, 2026	Change
LIABILITIES			
Current liabilities:			
Short-term debt	307,269	287,913	19,356
Notes and accounts receivable:			
Trade	314,656	291,296	23,360
Construction	82,487	97,154	(14,667)
Affiliated companies	1,336	1,399	(63)
	398,479	389,849	8,630
Accrued income taxes	33,333	53,202	(19,869)
Accrued liabilities	291,609	280,017	11,592
Short-term operating lease liabilities	37,944	36,549	1,395
Other current liabilities	188,789	210,742	(21,953)
Total current liabilities	1,257,423	1,258,272	(849)
Non-current liabilities:			
Long-term debt	668,333	607,034	61,299
Accrued pension and severance costs	24,909	25,515	(606)
Long-term operating lease liabilities	96,817	95,517	1,300
Other non-current liabilities	216,270	223,053	(6,783)
Total non-current liabilities	1,006,329	951,119	55,210
Total liabilities	2,263,752	2,209,391	54,361
EQUITY			
FUJIFILM Holdings shareholders' equity			
Capital	40,363	40,363	-
Common stock, without par value:			
Authorized: 2,400,000,000 shares			
Issued: 1,234,150,284 shares			
Retained earnings	3,138,207	3,117,407	20,800
Accumulated other comprehensive income	787,288	736,167	51,121
Treasury stock, at cost	(67,374)	(54,387)	(12,987)
Total FUJIFILM Holdings shareholders' equity	3,898,484	3,839,550	58,934
Noncontrolling interests	5,065	4,835	230
Total equity	3,903,549	3,844,385	59,164
Total liabilities and equity	6,167,301	6,053,776	113,525

Note: Details of accumulated other comprehensive income (loss)

	As of June 30, 2026	As of March 31, 2026	Change
Foreign currency translation adjustments	744,556	694,154	50,402
Pension liability adjustments	42,732	42,013	719

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

1st Quarter ended June 30 Amount Unit: Millions of yen

	Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026		Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025		Change	
					Amount	%
	%		%			
Revenue:	100.0	826,493	100.0	749,482	77,011	10.3
Cost of sales:	60.9	503,075	58.3	436,911	66,164	15.1
Gross profit	39.1	323,418	41.7	312,571	10,847	3.5
Operating expenses:						
Selling, general and administrative	27.8	229,949	26.2	196,643	33,306	16.9
Research and development	5.1	42,285	5.4	40,637	1,648	4.1
	32.9	272,234	31.7	237,280	34,954	14.7
Operating income	6.2	51,184	10.0	75,291	(24,107)	(32.0)
Other income (expenses):						
Interest and dividend income		3,104		3,112	(8)	
Interest expense		(1,859)		(2,453)	594	
Foreign exchange gains (losses), net		(495)		(5,984)	5,489	
Gains (losses) on equity securities, net		1,978		(659)	2,637	
Other, net		(1,812)		2,647	(4,459)	
	0.1	916	(0.4)	(3,337)	4,253	-
Income before income taxes	6.3	52,100	9.6	71,954	(19,854)	(27.6)
Income taxes	1.8	15,154	2.8	20,829	(5,675)	(27.2)
Equity in net earnings of affiliated companies	0.1	630	0.4	2,698	(2,068)	(76.6)
Net income	4.5	37,576	7.2	53,823	(16,247)	(30.2)
Less: Net (income) loss attributable to the noncontrolling interests	0.0	(152)	0.0	(56)	(96)	-
Net income attributable to FUJIFILM Holdings	4.5	37,424	7.2	53,767	(16,343)	(30.4)

(Consolidated Statements of Comprehensive Income)

1st Quarter ended June 30 Amount Unit: Millions of yen

	Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026	Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025	Change
Net income	37,576	53,823	(16,247)
Other comprehensive income (loss), net of tax:			
Foreign currency translation adjustments	50,487	2,429	48,058
Pension liability adjustments	719	(211)	930
Unrealized gains on derivatives	-	40	(40)
Total	51,206	2,258	48,948
Comprehensive income	88,782	56,081	32,701
Less: Comprehensive (income) loss attributable to noncontrolling interests	(237)	(128)	(109)
Comprehensive income attributable to FUJIFILM Holdings	88,545	55,953	32,592

(3) Consolidated Statements of Cash Flows

Amount Unit: Millions of yen

	Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026	Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025	Change
Operating activities			
Net income	37,576	53,823	(16,247)
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	50,422	40,853	9,569
(Gains) losses on equity securities	(1,978)	659	(2,637)
Equity in net (gains) losses of affiliated companies, net of dividends received	(152)	(2,493)	2,341
Changes in operating assets and liabilities:			
Notes and accounts receivable	63,235	60,162	3,073
Inventories	(60,021)	(52,280)	(7,741)
Notes and accounts payable - trade	20,724	2,921	17,803
Changes in other current assets	(8,203)	(13,129)	4,926
Accrued income taxes and other liabilities	(5,565)	4,916	(10,481)
Others	(3,745)	(674)	(3,071)
Subtotal	54,717	40,935	13,782
Net cash provided by operating activities	92,293	94,758	(2,465)
Investing activities			
Purchases of property, plant and equipment	(107,794)	(119,998)	12,204
Purchases of software	(9,765)	(9,993)	228
Sales of property, plant and equipment	1,686	―	1,686
Proceeds from sales and maturities of marketable and investment securities	786	2,365	(1,579)
Purchases of marketable and investment securities	(314)	(595)	281
(Increase) decrease in time deposits, net	(1,978)	(1,350)	(628)
Increase in investments in and advances to affiliated companies	―	(81)	81
Acquisitions of businesses, net of cash acquired	―	(1,183)	1,183
Proceeds from sale of businesses, net of cash and cash equivalents disposed of	―	6,926	(6,926)
Others	(7,522)	3,926	(11,448)
Net cash used in investing activities	(124,901)	(119,983)	(4,918)
Financing activities			
Proceeds from long-term debt	100,000	100,000	0
Repayments of long-term debt	(689)	(40,616)	39,927
Increase (decrease) in short-term debt, net	(20,816)	2,796	(23,612)
Cash dividends paid to shareholders	(42,187)	(42,170)	(17)
Subsidiaries’ cash dividends paid to noncontrolling interests	(7)	(89)	82
Sales (purchase) of stock for treasury	(30,002)	(2)	(30,000)
Capital transactions with noncontrolling interests	―	141	(141)
Others	3	17	(14)
Net cash provided by financing activities	6,302	20,077	(13,775)
Effect of exchange rate changes on cash and cash equivalents	6,404	(6,991)	13,395
Net decrease in cash and cash equivalents	(19,902)	(12,139)	(7,763)
Cash and cash equivalents at beginning of period	170,553	172,111	(1,558)
Cash and cash equivalents at end of period	150,651	159,972	(9,321)

(4) Notes to Consolidated Financial Statements

(Note Relating to the Going Concern Assumption)

None.

(Segment Information)

a. Revenue

Amount Unit: Millions of yen

	Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026		Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025		Change	
					Amount	%
Revenue:	Composition (%)		Composition (%)			
Healthcare	31.1	256,824	30.5	228,471	28,353	12.4
Electronics	15.4	127,650	13.6	102,140	25,510	25.0
Business Innovation	33.1	273,243	36.5	273,563	(320)	(0.1)
Imaging	20.4	168,776	19.4	145,308	23,468	16.2
Consolidated total	100.0	826,493	100.0	749,482	77,011	10.3

b. Expenses

Amount Unit: Millions of yen

	Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026	Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025	Change	
			Amount	%
R&D expenses				
Healthcare	13,757	14,757	(1,000)	(6.8)
Electronics	8,079	7,022	1,057	15.1
Business Innovation	14,998	13,953	1,045	7.5
Imaging	4,264	3,010	1,254	41.7
Subtotal	41,098	38,742	2,356	6.1
Corporate	1,187	1,895	(708)	(37.4)
Consolidated total	42,285	40,637	1,648	4.1
Other operating expenses				
Healthcare	255,744	209,436	46,308	22.1
Electronics	88,443	72,595	15,848	21.8
Business Innovation	259,690	244,041	15,649	6.4
Imaging	121,119	100,529	20,590	20.5
Subtotal	724,996	626,601	98,395	15.7
Corporate	8,028	6,953	1,075	15.5
Consolidated total	733,024	633,554	99,470	15.7

c. Operating income

Amount Unit: Millions of yen

	Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026		Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025		Change	
					Amount	%
Operating Income (Loss):	Margin (%)		Margin (%)			
Healthcare	(4.9)	(12,677)	1.9	4,278	(16,955)	-
Electronics	24.4	31,128	22.1	22,523	8,605	38.2
Business Innovation	(0.5)	(1,445)	5.7	15,569	(17,014)	-
Imaging	25.7	43,393	28.7	41,769	1,624	3.9
Total		60,399		84,139	(23,740)	(28.2)
Corporate expenses etc.		(9,215)		(8,848)	(367)	-
Consolidated total	6.2	51,184	10.0	75,291	(24,107)	(32.0)

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, drug discovery support such as iPS cells, cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Electronics:	Semiconductor materials, display materials, industrial equipment, fine chemicals, etc.
Business Innovation:	Solutions and services, digital MFPs, equipment and materials for graphic communications, inks and industrial inkjet printheads, etc.
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

d. Total Assets

Amount Unit: Millions of yen

	As of June 30, 2026	As of March 31, 2026	Change	
			Amount	%
Total assets:				
Healthcare	3,300,741	3,227,034	73,707	2.3
Electronics	826,360	821,265	5,095	0.6
Business Innovation	1,440,496	1,469,229	(28,733)	(2.0)
Imaging	477,057	423,126	53,931	12.7
Subtotal	6,044,654	5,940,654	104,000	1.8
Corporate	122,647	113,122	9,525	8.4
Consolidated total	6,167,301	6,053,776	113,525	1.9

e. Depreciation and amortization, and Capital expenditures

Amount Unit: Millions of yen

	Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026	Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025	Change	
			Amount	%
Depreciation and amortization:				
Healthcare	24,027	17,178	6,849	39.9
Electronics	7,738	7,346	392	5.3
Business Innovation	12,664	11,516	1,148	10.0
Imaging	4,802	3,708	1,094	29.5
Corporate	1,191	1,105	86	7.8
Consolidated total	50,422	40,853	9,569	23.4
Capital expenditures:				
Healthcare	82,928	109,104	(26,176)	(24.0)
Electronics	5,863	5,006	857	17.1
Business Innovation	12,973	12,417	556	4.5
Imaging	7,282	2,956	4,326	146.3
Corporate	2,134	939	1,195	127.3
Consolidated total	111,180	130,422	(19,242)	(14.8)

f. Overseas revenue (Destination Base)

Amount Unit: Millions of yen

	Three months ended June 30, 2026 From April 1, 2026 To June 30, 2026		Three months ended June 30, 2025 From April 1, 2025 To June 30, 2025		Change	
					Amount	%
Revenue:	Composition (%)		Composition (%)			
Domestic	30.7	253,728	34.3	256,872	(3,144)	(1.2)
Overseas:						
The Americas	21.2	175,266	20.7	155,321	19,945	12.8
Europe	18.0	148,443	16.6	124,559	23,884	19.2
Asia and others	30.1	249,056	28.4	212,730	36,326	17.1
Subtotal	69.3	572,765	65.7	492,610	80,155	16.3
Consolidated total	100.0	826,493	100.0	749,482	77,011	10.3

Note: The presentation of the overseas revenue (Destination Base) has been classified and disclosed based on the customer’s location.

(Note on Significant Changes to FUJIFILM Holdings Shareholders' Equity)
None.

(Significant Subsequent Events)
None.